Drug Trial Radar · NCT03934684
Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
101
Actual
Start
Sep 16, 2019
Primary completion
Mar 23, 2023
Study completion Jun 27, 2025
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- May 2, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To characterize safety associated with the use of Kyprolis under the locally approved label.
Conditions
- Relapsed Refractory Multiple Myeloma
Interventions
Drug: Carfilzomib + DexamethasoneDrug
Drug: Carfilzomib + Dexamethasone * Carfilzomib will be administered as a 30-minute infusion. * Dexamethasone will be taken by mouth or intravenously.
Drug: Carfilzomib + Lenalidomide + DexamethasoneDrug
Drug: Carfilzomib + Lenalidomide + Dexamethasone * Carfilzomib will be administered as a 10 minute infusion. * Lenalidomide will be taken orally. * Dexamethasone will be taken by mouth or intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)Time frame: From the first dose date of any IP until the end of trial; median (min, max) time on trial was 8.7 (0.1, 37.2) months
- Number of Participants Who Experienced Serious TEAEsTime frame: From the first dose date of any IP until the end of trial; median (min, max) time on trial was 8.7 (0.1, 37.2) months
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Yashoda Hospital
Hyderabad, Andhra Pradesh, India
Apollo Hospital
Hyderabad, Andhra Pradesh, India
M S Ramaiah Memorial Hospital
Bangalore, Karnataka, India
K L E S Dr Prabhakar Kore Hospital and Medical Research Centre
Belagavi, Karnataka, India
Cytecare Cancer Hospitals
Bengaluru, Karnataka, India
Aster Medcity
Kochi, Kerala, India
Government Medical College
Kozhikode, Kerala, India
Tata Memorial Hospital
Mumbai, Maharashtra, India
Mumbai Oncocare Center
Mumbai, Maharashtra, India
Navsanjeevani Hospital
Nashik, Maharashtra, India
Heath Care Group Manavata Cancer Centre
Nashik, Maharashtra, India
Deenanath Mangeshkar Hospital and Research Centre
Pune, Maharashtra, India
Jawaharlal Institute of Postgraduate Medical Education and Research
Puducherry, Puducherry, India
Cancer Institute WIA
Chennai, Tamil Nadu, India
Thangam Cancer Centre
Namakkal, Tamil Nadu, India
Valentis Cancer Hospital
Meerut, Uttar Pradesh, India
Netaji Subhash Chandra Bose Cancer Research Institute
Kolkata, West Bengal, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.